The performances of four immunoassays (DRI amphetamines, DRI ecstasy, Abuscreen ONLINE amphetamines, and a modified Abuscreen ONLINE amphetamines) were evaluated for control failure rates, sensitivily, and specificity for amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphelamine (MDMA). The two DRI reagents and the ONLINE reagents were run according to manufacturer specifications using a Roche Hitachi Modular DDP system. The modified ONLINE reagent was calibrated with MDMA and had 16raM sodium periodate added to the R2 reagent. These assays were run on approximately 27,500 human urine samples and 7000 control urine samples prepared at 350 and 674 ng/mL over the course of 8 days. All assays were calibrated using a single point, qualitative cutoff standard with the manufacturerrecommended compound at the Department of Defense cutoff (500 ng/mL). Gas chromatography-mass spectrometry (GC-MS) confirmation was conducted on screened-positive samples. Control performance for the manufacturer recommended assays was excellent, with a maximum qualitative control failure rate of 2.03%. The modified ONLINE reagent demonstrated poor control performance with a maximum failure rate of 38.3% and showed no improved MDMA sensitivity when compared with the ONLINE reagent; the confirmation rate (20%) was improved when compared with the production ONLINE reagent (8%). The DRI ecstasy reagent provided improved sensitivity for MDMA as 9 The opinions contained in the publication are not to be construed as official or as reflecting the views of the Department of Defense or the Department of the Navy, compared with the ONLINE reagent, with approximately 23% more samples screening and confirming positive for MDMA and a confirmation rate of approximately 90%. The DRI methamphetamine reagent had a low confirmation rate (6% or less) and produced numerous positives for samples with only ephedrine or pseudoephedrine present.
Introduction
Rising concerns about ecstasy usage both in the population at large (1) and within the military population (2-5) have necessitated increased attempts to improve the length of detection time windows and sensitivities for 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in forensic urine drug testing (6) . A resurgence of methamphetamine (MTH) and amphetamine (AMP) popularity (7) has continued to provide pressure to improve the detection sensitivities for these drugs as well. The Department of Defense (DoD) efforts to accomplish this have been confounded because of production efficiency issues (2--4) demonstrating some of the potential pitfalls in implementation. In an effort to achieve improved sensitivity for MDMA as well as MTH usage, continuous evaluation of screening reagents has been necessary.
Several published studies have evaluated aspects of screening reagents that are commonly used in urine testing for drugs of abuse. These studies include the evaluation of Abbott TDx AMP/MTH II (8) (9) (10) , Abuscreen ONLINE (8) (9) (10) (11) , Syva EMIT (8) (9) (10) 12) , Microgenics CEDIA (8) , Diagnostic Products Corporation radioimmunoassay (RIA) (9, 10) , and DRI (12) . All of the studies have reported good agreement between screening results and confirmatory methods. However, all of the studies have utilized small sample groups with as few as 20 samples (9) and a maximum of 2964 samples (10) . Although these results provide a good indication of the performance of the assays, they do not give an indication of the likely performance of the reagents over tens of thousands of samples.
This type of performance estimation is of particular importance, given that all of the reagents have some cross-reactivity to over-the-counter compounds such as ephedrine and pseudoephedrine and other interfering compounds that could produce positive screening results, but will not confirm positive for AMP, MTH, MDA, or MDMA (8) . In large production environments, relatively small control failure rates or cross-reactive false-positive screen rates can produce efficiency problems in the confirmation process, thereby increasing overall sample testing costs.
The purpose of this study was to evaluate the performance of three commercially available immunoassay reagents with specificity for AMP/MTH or MDA/MDMA and one reagent that was modified to attempt to improve its sensitivity for MDA/ MDMA. The design of the evaluation was to mirror production conditions in a laboratory processing 3000-4000 samples per day. All of the reagents were evaluated over a large number of samples analyzed over the course of several days for the performance of controls and for their agreement with a gas chromatography-mass spectrometry (GC-MS) confirmatory method at two different confirmation cutoff concentrations (500 ng/mL and 250 ng/mL).
Materials and Methods
Twenty-seven thousand five hundred human urine samples randomly collected and submitted to the laboratory as part of the DoD directed drug-testing program were analyzed on the D modules of a Roche Hitachi modular DDP system (Indianapolis, IN) for AMP, MTH, MDA, and MDMA using the Roche Abuscreen ONLINE immunoassay specific for AMP/MTH as the production reagent (production, unmodified ONLINE). In parallel, these samples were also assayed with the Microgenics DRI AMP/MTH and DRI ecstasy reagents (Fremont, CA) that is specific for AMP/MTH and MDA/MDMA. The Abuscreen ON-LINE assay was modified in an attempt to improve the assay's sensitivity and specificity to MDMA. Specifically, sodium periodate, purchased from Fisher Scientific (Pittsburgh, PA), was added to the R2 reagent at a final concentration of 16raM. Testing was conducted on 8 consecutive production days. These assays were run in accordance with the manufacturer-recommended instrument parameters.
For the production ONLINE assay, the calibration standard was prepared by Biopool (Ventura, CA), containing d-AMP at 500 ng/mL. The calibrators for the DRI reagents were manufactured in-house using standard materials purchased from Cerilliant (Austin, TX). These calibrators contained 500 ng/mL MDMA for the DRI ecstasy reagent and 500 ng/mL d-MTH for the DRI AMP/MTH reagent. The modified ONLINE reagent was calibrated using the same MDMA calibrator.
For the production ONLINE assay, the controls included a low multiconstituent control with 350 ng/mL d-AMP manufactured in-house using standard material purchased from Cerilliant and Roche certified drug-free urine. A high control containing 675 ng/mL d-AMP was manufactured by Biopool. The other assays were controlled on the same drug with which they were calibrated in single-constituent controls manufactured in-house from standard materials purchased from Cerilliant and Roche certified drug-free urine.
All assays were run as qualitative assays. Assays were calibrated daily prior to running samples. For all of the assays, a single-point blank calibration was utilized per manufacturer specifications. This result was normalized to a value of 100. Thus, any result greater than or equal to 100 was considered a positive screening result.
All confirmations were conducted using a solid-phase extraction method after pretreatment with sodium periodate and GC-MS analysis as described in Stout et al. (13) . The cutoff calibrator was manufactured in-house using 500 ng/mL of d-MTH, d-AMP, MDMA, and MDA from Cerilliant and Roche certified drug-free urine. Controls at 250 and 625 ng/mL were also manufactured in-house using the same materials. All confirmation batches included a cutoff calibrator (500 ng/mL), negative control, a low control (375 ng/mL), and a high control (625 ng/mL). 1.15%. The results of each assay were consistent with the relative cross-reactivities to ephedrine and pseudoephedrine reported in the manufacturer's package inserts and were as would be expected with the addition of sodium periodate in the screening process. Table It presents the qualitative control failure rates for each of the reagents. Controls were considered failures if the low control had a result equal to or greater than 100 or if a high control had a result less than 100. The results are expressed as a percentage of the total number of controls run for that reagent. Notably, the modified ONLINE reagent produced poor control performance, suggesting that sodium periodate in the reagent may result in a D-module inaccuracy. All of the other reagents had few control failures. No trend in the control performance was observed over the test period for any of the reagents. Table III presents the distribution of the numbers of samples that were positive for each of the target analytes above the 500-ng/mL confirmation cutoff. This table also presents the confirmation rate when compared with the initial screening resuits. A second screening of the production ONLINE positives eliminated some presumptive positives. Department of Navy standard procedures require the screening of a second aliquot of any initial presumptive positive by the same screening technology. The calculation of this confirmation rate also accounts for samples that were also positive for other drug classes. The positive rate is a comparison of the number of samples confirming positive relative with the total number of samples screened positive with each reagent. The highest confirmation rate was seen for the DRI ecstasy reagent (87%), and the lowest confirmation rate was observed for the DRI AMP reagent at approximately 5.8%. All of the samples that were presumptively positive by the DRI AMP reagent (n = 1104) and that were not positive by any other reagent were confirmed without pretreating the samples with sodium periodate (13) . This allowed for the determination of the presence of ephedrine, pseudoephedrine, and phenylpropanolamine. Notably, each of the 1104 samples contained pseudoephedrine without the presence of any of the target analytes. The production ONLINE reagent had a confirmation rate of approximately 7.9%, and this was markedly improved by the addition of sodium periodate in the modified ONLINE reagent to approximately 20%. In comparison, for our laboratory's typical confirmation rate for the ONLINE reagent, of 330,562 samples screened in the six months prior to the study period with the production ONLINE reagent using the same equipment and parameters as this study, we obtained 2223 screened positive samples, of which 252 samples confirmed positive for AMP, MTH, MDA, or MDMA by GC-MS. This was an 11.3% confirmation rate and a 0.08% positive rate, which was consistent with the positive rate observed in the study, indicating a consistent performance during the study as under normal operating conditions. The results indicate that 23% more MDMA-positive samples would be detected with the DRI ecstasy reagent when compared with the current production ONLINE reagent. Though the objective was to determine if calibrating the ON-LINE reagent on MDMA would increase the detection of MDMA-positive samples, no increase in detection was observed.
Results and Discussion
Although overall usage of drugs has declined in the DoD, ecstasy use has been increasing, necessitating an improvement in our ability to detect MDMA for a longer time frame (5) . Table  IV presents the same data as seen in Table III with the application of a confirmation cutoff of 250 ng/mL. Most notably, the MTH-positive rate more than doubled. More samples would be considered positive for MDA; however, these samples were already positive for MDMA above 500 ng/mL. The confirmation rates compared with the initial screening results were subsequently improved for all of the reagents, while maintaining the 
Conclusions
The performance of the reagents indicated that the manu- Table V facturer-recommended application of these assays produced good control performances at the concentrations used. The assays had mixed ability to distinguish their target analytes efficiently. The modified application of the ONLINE assay drastically impacted the control performance, but did reduce the number of positive samples due to over-the-counter sympathomimetic amines. The overall production viability of this modified application is questionable because of the quantity of rework that the control failures would necessitate. The DRI ecstasy reagent did provide increased sensitivity for MDMAwith a good confirmation rate and few false-positive screening results. The difficulty for production is the need to use this reagent and another more AMP/MTH-specific reagent to test for the suite of amphetamine class compounds.
The AMP/MTH-specific reagents (ONLINE and DRI) both reliably detected AMP/MTH-positive samples. However, both assays were also sensitive to ephedrine/pseudoephedrine and had large numbers of samples that were positive only for ephedrine/pseudoephedrine. Though ephedrine and pseudoephedrine were not quantitated in our test set, qualitative chromatography indicated very large concentrations of ephedrine and/or pseudoephedrine present in many of the samples that screened positive for AMP/MTH. The rate of positive screens obtained by the DRI AMP reagent (more than 4% of tested samples) that contain ephedrine or pseudoephedrine is consistent with Blanck et al. (14) , indicating a 7% rate of over-the-counter diet aid use among adults over the age of 18. This pattern of positives also suggests that many people are taking large quantities of the compounds, which is consistent with conclusions by Gurley et al. (15) . Gurley et al. (16) also demonstrated the dramatic inconsistency that many diet aid preparations may have in ephedrine and ephedrine alkaloid concentrations that could lead to individuals having dosage regimens dramatically larger than intended. Thus, even though the manufacturers report low cross-reactivities (0.1-0.6% as reported in the manufacturer's package inserts) to compounds such as ephedrine, the high concentrations achieved by a substantial number of users lends to low confirmation rates. This highlights the need for continued work on improving the specificity of AMP/MTH reagents to develop a productionefficient reagent.
